Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 5/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023344 | 0.87 | SCN1A (0.53) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL28532026 | 0.85 | KMT2A (0.56) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL18687104 | 0.83 | SCN1A (0.50) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1818116 | 0.82 | SCN1A (0.49) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL697518 | 0.80 | — | — | |
| SCHEMBL12879857 | 0.77 | SCN1A (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL9330353 | 0.77 | SCN1A (0.49) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL18195619 | 0.77 | CHRM3 (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL14476943 | 0.77 | SCN1A (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1331414 | 0.77 | SCN1A (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | claimed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | claimed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | SCN1A 1608/4885SCN2A 1514/4885SCN3A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.